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Summary An increased incidence of colonic cancer is associated with chronic inflammatory bowel disease. Sulphasalazine, metronidazole and more recently, modified forms of 5-aminosalicylic acid are used for maintenance therapy of inflammatory bowel disease. In a series of experiments, we used the 1,2- dimethylhydrazine animal model of colonic cancer in conjunction with these drugs, to study the effect on the development of colon cancer. Inbred male Wistar rats were divided into groups receiving orally: metronidazole 18mgKg-'dy-'; sulphasalazine 60mgKg-'dy-'; 5-aminosalicylic acid 30 and 60mgKg-'dy-' and olsalazine 60 mg Kg-' dy-' administered daily. Half of each group also received weekly injections of DMH 40mg Kg-'. Metronidazole, sulphasalazine and 30 mg Kg-' dy-' 5-aminosalicylic acid were co-carcinogenic, increasing either the number of cancers or tumour size. In contrast 60 mg Kg-' dy-' 5-aminosalicylic acid inhibited tumour size and olsalazine had no effect. These results may have a bearing on long term maintenance therapy in inflammatory bowel disease.
An increased incidence of colonic cancer has long been
known to be associated with inflammatory bowel disease,
especially ulcerative colitis (Isabell & Levin, 1988). The
causality of the association is now generally accepted. With
ulcerative colitis, the known risk factors include the extent
and the duration of the disease. The incidence is much
higher, in those whose disease starts at a younger age and
where there is total colonic involvement.
It is now common clinical practice to use sulphasalazine
and to a lesser extent, metronidazole for maintenance
therapy in the treatment of chronic inflammatory bowel
disease (Rosen et al., 1982). Could it be that these drugs
influence the subsequent development of carcinoma?
Using an accepted animal model (the production of colon
cancer in rats using a chemical carcinogen, 1,2-dimethyl-
hydrazine [DMH]), high dosage metronidazole has been
shown to be co-carcinogenic (Sloan et al., 1983; A-Kareem et
al., 1984). A number of published clinical case reports also
implicate metronidazole in the production of colonic cancer
(Krause et al., 1985). More recently, it has been postulated
that sulphasalazine may play a role, in the subsequent
development of colonic cancer in ulcerative colitis patients
(Lashner et al., 1989).
The constituents of sulphasalazine are sulphapyridine and
5-aminosalicylic acid (5-ASA). While sulphapyridine has no
apparent beneficial effect in ulcerative colitis, it induces many
of the side effects of sulphasalazine. In an earlier experiment
we found that sulphapyridine had no effect on the size, or
growth, of colonic carcinomas, in animals receiving DMH
(unpublished data).
The active moiety of sulphasalazine is 5-ASA. However,
5-ASA taken orally is absorbed rapidly from the small intes-
tine (Schroder & Campbell, 1972); hence the amount of
5-ASA reaching the colon may be inadequate for therapy
(Nielsen & Bondesen, 1983). To overcome this difficulty,
olsalazine sodium (containing two molecules of 5-ASA joined
by an azo bond), has been developed. It may be better
tolerated, than sulphasalazine (Meyers et al., 1987).
We used the rat animal model to study the effects of
several therapeutic drugs on colonic cancer production.
Treatment groups included: metronidazole (in a low dosage
not previously studied), sulphasalazine, 5-aminosalicylic acid
and olsalazine sodium.
Materials and methods
Inbred male Wistar rats were randomly allocated to study
groups, according to weight. Each group contained six to 18
rats depending on the availability of males within litters. Rats
were housed individually, in plastic cages with stainless steel
tops and bottoms suspended over trays of wood shavings.
Room temperature was maintained at 20°C ± 2°C, with
average humidity 70% and light and dark in a 12/12 h cycle.
After separation as weanlings, rats were housed without
treatment for 3 weeks to acclimatise. The rats weighed 160-280 grams at commencement. Pair-feeding for 3 weeks
produced no significant difference in weight change between
groups. Thereafter, all animals received food (rat and mouse
cubes, 3.8% fibre content, Doust & Rabbidge) and tap water
ad libitum.
For each drug studied, one group of rats received one
subcutaneous injection per week of 1,2-dimethylhydrazine (Sigma Chemical Company, St Louis, USA), 40 mg Kg-' for
20 consecutive weeks. An equal number of rats received the
drug but no DMH. The DMH was prepared in distilled
water. Drug dosages were calculated according to the
therapeutic dosage equivalent for humans. The drugs were
administered orally by daily intubation: metronidazole
18 mgKg- ' dy- ; sulphasalazine 60 mg Kg-' dy-'; 5-amino-
salicylic acid 30 and 60 mg Kg-' dy-' and olsalazine
60 mgKg- dy'-l. Two other groups were included: 'no drug,
no DMH' and 'DMH only'. At sacrifice, the researchers and
histopathologist were unaware as to the rat's treatment
group.
Development of colonic cancer was assessed at 20 weeks, with sacrifice and pathological investigations on one rat, which had received DMH injections only. Colonic adenocar-
cinomas had developed. The remaining animals were then
anaesthetised with ether, and desanguinated via the aortic
bifurcation. The large bowel and selected segments of the
small bowel, liver, kidney and pancreas were then resected.
The large bowel was opened lengthwise and washed with
normal saline. The location, appearance and the diameter of
lesions were recorded. Specimens were fixed in formal saline
and subsequently examined histologically (Fisher et al., 1981; Nauss et al., 1984).
All the lesions were examined macroscopically by one
operator (FP) and identified as either lymphoid aggregates or
tumours. Lymphoid nodules were smooth flat and regular in
appearance. The location and distribution of lymphoid nodules in the rat bowel, has been previously reported (Nauss
et al., 1984). Tumours were rough, highly vascularised, irregular shaped and distributed either in association with
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lymphoid tissue, randomly or aggregated. The pathological
features of DMH induced colonic tumours in the rat, have
been described extensively. Microinvasive, polypoid and flat
carcinomas occur. In rats there is little or no evidence of a
polyp-to-cancer sequence as with human colonic cancer
(Sunter et al., 1978; Nauss et al., 1984).
The histologist (RC) validated the macroscopic visual
assessment of the lesions by cutting and examining sections.
Because of the large number of tumours produced, an
average of four tumours per rat were examined. All medium
and large tumours could be accurately diagnosed grossly and
all small tumours could be distinguished from lymphoid
nodules, except for rare cases of tumours developing in lym-
phoid nodules.
Analysis of variance and corrected Chi-squared was used
for analysis. The Students t-test was used to compare mean
values. A probability of <0.05 was taken as significant.
Ethics committee approval was obtained for this study ac-
cording to the guide-lines of Australia's National Health and
Medical Research Council.
Results
Up to the final week of the study there was no signficant
difference (ANOVA P<0.05) between weekly consumption
of diet or weight gain within or between any of the groups.
In the last week some weight loss occurred among rats
receiving DMH. Soft, dark yellow faeces were characteristic
of the rats receiving sulphasalazine.
Although the chronological duration of administration of
the carcinogen and the therapeutic drugs was concurrent,
technically the therapeutic drugs were not administered
simultaneously with the DMH. They were given by different
routes (by subcutaneous injection for the carcinogen and
orally for the drugs) and the weekly injection of DMH would
have been metabolised within 24 h, whereas the therapeutic
drugs were administered daily, throughout the experiment.
Therefore, any competitive metabolic effect would not be
expected to extend beyond the 24 h period following the
weekly carcinogen injection.
Colonic adenocarcinomas occurred in all of the rats receiv-
ing DMH injections, but not in any of the rats not receiving
the carcinogen. The tumours were all adenocarcinomas of
varying histological type and differentiation, according to
WHO classifications. The small tumours were mostly
polypoid, well differentiated adenocarcinomas. A minority
were intramucosal and could be defined as 'adenomas', if
there was no invasion through the muscularis mucosae.
Most tumours showed at least minimal invasion into the
submucosa. The architectural and cytological features were
similar in those that were intramucosal and those that were
invasive. Unlike human colonic carcinoma, there was no
clear adenoma-cancer sequence. The 'adenomas' appeared to
Figure I Small polypoid adenocarcinoma with micro-invasion of
muscularis mucosae by single gland. Magnification x 54.
be small early cancers differing only by absence of invasion
through the muscularis mucosae (Figures 1 and 2).
Larger diameter tumours tended to have deep invasion of
muscularis propria and serosa (Figures 3 and 4). The large
carcinomas also tended to contain areas of mucinous
adenocarcinoma and/or poorly differentiated adenocar-
cinoma, including signet ring cell forms. A minority of car-
cinomas appeared to arise in lymphoid nodules with intact
overlying normal mucosa.
Differences, in both numbers and size of tumours between
groups occurred. There was a significant increase in tumour
numbers (ANOVA P<0.05) in the groups receiving metro-
nidazole, sulphasalazine and 30 mg Kg-' dy-' 5-aminosali-
cylic acid, compared with the rats receiving DMH only
(Table I). In all groups, the majority of tumours occurred in
Figure 2 Small polypoid adenocarcinoma with early invasion
into submucosa. Magnification x 54.
Figure 3 Large adenocarcinoma with invasion through mus-
cularis propria into serosa. Magnification x 30.
Figure 4 Usual well differentiated adenocarcinoma. Magni-
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the left colon. However, the percentage of tumours, occurring
in the right colon, increased significantly with sulphasalazine
(Table I).
We tabulated the size of the tumours in the different
groups (Table II). No tumours with a diameter greater than
10mm were found in the group receiving DMH alone. All
other groups, with the noteworthy exception of the group
receiving 60 mg Kg- 1 dy ' 5-ASA had tumours greater than
10mm in diameter. In addition, there was a significant pro-
portion, of smaller tumours (< 5 mm), in the group receiving
60 mg Kg-' dy-' 5-ASA.
Discussion
In this study, metronidazole 18 mg Kg-' dy '; sulphasalizine
60 mg Kg- dy'l and 5-aminosalycylic acid 30 mg Kg'- dy'l
exhibited a co-carcinogenic effect on the number of colonic
carcinomas produced in rats receiving DMH. The results for
olsalazine were equivocal and 60 mg Kg- dy-' 5-ASA had
no co-carcinogenic effect (Table I).
The 18 mg Kg-' dy 'dosage of metronidazole used in
these experiments is considerably less than the 50 mg-
Kg- dy'1 previously reported. The lower dose is closer to
the therapeutic dosage used in maintenance therapy of
inflammatory bowel disease in humans. Despite this dosage
reduction, there is still a significant co-carcinogenic effect
with metronidazole. Further dose response studies in this
model may determine if there is a minimum co-carcinogenic
dosage with metronidazole.
The inclusion of metronidazole in this study and the rep-
roducible findings, of a co-carcinogenic effect, provides a
valid comparison for the results which we obtained with
other drugs, not previously reported in this model. The possi-
ble mechanism of the co-carcinogenic action of metro-
nidazole remains obscure. An effect of absorbed metabolites
of metronidazole on colonic bacteria has been postulated
(Speck et al., 1976).
Figure 5 Example ofcolonic mucosa (normal) from a rat receiv-
ing metronidazole, but no dimethylhydrazine. Magnification x
120.
Figure 6 Example of colonic mucosa (normal) from a rat receiv-
ing olsalazine, but no dimethylhydrazine. Magnification x 120.
Table I Comparison of site and numbers (%) of total colonic tumours in groups receiving either dimethylhydrazine only or a
therapeutic drug as well as DMH
Number oftumours per group
Left colon Right colon Caecum Total Mean ± s.e. Rats in group
n % n % n % n n
mgKg' wk-'
DMH 40 49 (70.0) 21 (30.0) 0 (0.0) 70 6.4± 0.69 11
mg Kg-' wk-'
+ metronidazole 18 190 (77.2)b 50 (20.3)b 6 (2.5) 246 13.7 ± 1.52a 18
+ sulphasalazine 60 87 (61.7)b 54 (38.3)b 0 (0.0) 141 11.8 ± 2.16a 12
+ olsalazine 60 46 (76.7) 14 (23.3) 0 (0.0) 60 10.0 ± 2.75 6
+ 5-ASA 30 73 (75.3) 24 (24.7) 0 (0.0) 97 13.9 ± 3.06a 7
+ 5-ASA 60 40 (78.4) 11 (21.6) 0 (0.0) 51 8.5 ± 3.68 6
aCompared to DMH alone, the mean number oftumours per rat differs significantly (t-test, P<0.05).bBetween metronidazole
and sulphasalazine groups the proportion of tumours in the right and left colon is significant (corrected Chi-squared, df = 1,
P<0.001).
Table II Comparative size in millimetres (%) of total colonic tumours occurring in groups of rats receiving either
dimethylhydrazine only or a therapeutic drug as well as DMH
Number and size oftumours per group
<5mm 5-9 mm > 10mm total >5mm Rats in group
n % n % n % n % n
mg Kg-'wk-'
DMH 40 48 (68.6) 22 (31.4) 0 (0.0) 22 (31.4) 11
mg Kg-' dy-'
+ metronidazole 18 173 (70.3) 52 (21.1) 21 (8.6)a 73 (29.7) 18
+ sulphasalazine 60 105 (74.5) 30 (21.3) 6 (4.2) 36 (25.5) 12
+ olsalazine 60 39 (65.0) 19 (31.7) 2 (3.3) 21 (35.0) 6
+ 5-ASA 30 61 (62.9) 22 (22.7) 14 (14.4)a 36 (37.1) 7
+ 5-ASA 60 48 (94.1)a 3 (5.9)a 0 (0.0) 3 (5.9)a 6
aCompared with DMH alone the proportion ofsmaller (or larger) tumours is significant (corrected Chi-squared, df= 1,
P<0.01).780 A.E. DAVIS et al.
The reported distribution of colonic tumours differs
according to variable study factors, such as the frequency
and dosage of DMH and the rat strain used in experiments
(Nauss et al., 1984; McGarrity et al., 1988). Even so, a
predominance of tumours occurring in the left colon is the
usual finding, therefore the shift to a right colon tumour
distribution among rats receiving both DMH and sulphasal-
zine, in our study, may be a significant finding, which war-
rants further study.
Pharmokenetic studies of sulphasalazine have shown that
70%, of this drug, reaches the colon unaltered. When
absorbed sulphasalazine, returned to the small intestine in
bile is included, 90% of the original dosage eventually
reaches the colon. In humans, from 1% to 7% of unchanged
sulphasalazine may be recovered in faeces (Schroeder &
Campbell, 1972).
Sulphazalazine inhibits the intestinal absorption of folate.
It has been postulated that sulphasalazine may cause mucosal
dysplasia secondary to folic acid deficiency (Selhub et al.,
1978; Clinical Nutrition Cases, 1988). The incidence of dys-
plasia in patients receiving sulphasalazine, for inflammatory
bowel disease, has been found to be greater than in patients
not receiving the drug (Lashner et al., 1989). Sulphasalazine
has been shown to be a competitive inhibitor of folate depen-
dent enzymes. However, in our studies, rat serum folate
levels were depleted due to sulphasalazine (subsequent
analysis), but secondary dyplasia was not observed. These
findings require further investigation.
In this study, low dosage 30 mg Kg- dy' 5-ASA,
appeared to be co-carcinogenic, while high dosage 60mg-
Kg-' dy' 5-ASA, had no such effect; indeed the higher dose
inhibited tumour size. This inhibitory effect parallels the in
vitro finding, that concentrations of 15mM 5-ASA inhibit
cancer cell growth, in human cancer cell lines (Desai et al.,
1989).
Because 5-ASA is absorbed in the small bowel, only 2% of
the total dose may be recovered in faeces (Nielsen &
Bondesen, 1983). Nevertheless, in our experiment, doubling
the dosage from 30 to 60 mg Kg-' dy ' had a beneficial
effect in the colon; as reflected in the reduction in size of
colonic tumours among rats in this treatment group.
Therefore, it seems appropriate to conclude that with the
60 mg Kg-ldy-1 5-ASA regime, in rats, sufficient 5-ASA
reaches the colon, to act locally on colonic mucosa.
As olsalazine is not absorbed in the small intestine, 95%
reaches the colon to be split by bacteria. The concentration
of 5-ASA in faeces, after administration of olsalazine, is
twice that after sulphasalazine (Lauritsen et al., 1984). Con-
sidering these characteristics, of olsalazine, we are unable to
explain why olsalazine was not equally as effective as 60 mg-
Kg-' dy' 5-ASA, in inhibiting tumour size, in this animal
model.
Although these results were obtained in the 1,2-dimethyl-
hydrazine animal model, there may be a stronger association
between this animal model, hydrazines and human colonic
cancer, than is at first apparent. Hydrazines are potent car-
cinogens. Humans may be exposed to hydrazines in their
environment. This chemical occurs as industrial and food
contaminants (Toth et al., 1975) and is also found in tobacco
(Liu et al., 1974).
In these studies, in an animal model, we have attempted to
assess the role of therapeutic drugs, used in maintenance
therapy of human inflammatory bowel disease, in the
development of colonic cancer. The next step may seem to be
to superimpose this cancer model on an animal model of
inflammatory bowel disease; to assess the combined effect.
However, because an inflammatory bowel disease model
would require the uses of cytotoxic chemicals, the combined
effects might confound, rather than simplify investigations.
From these experiments, it appears that therapeutic drugs
may, under certain conditions, act as co-carcinogens. Because
of the increasing tendency to use the drugs studied in long-
term maintenance therapy of inflammatory bowel disease,
these findings could well have clinical significance.
References
A-KAREEM, A.M., FLEISZER, D.M., RICHARDS, G.K., SENTERMAN,
M.K. & BROWN, R.A. (1984). Effect of long-term metronidazole
(MTZ) therapy on experimental colon cancer in rats. J. Surg.
Res., 36, 547;
CLINICAL NUTRITION CASES (1988). Sulphasalazine inhibits folate
absorption. Nutrition Rev., 46, 320.
DESAI, T.K., BULL, A.W., YANAMADALA, U., MOHIER, J.A. & LUK,
G.D. (1989). 5-aminosalicylic acid (5-ASA) inhibits human colon
cancer cell growth and suppresses ornithine decarboxylase
activity, possible through a post transcriptional mechanism.
Gastroenterology, 96, A120.
FISHER, E.R., PAULSON, J.D. & MORGAN, M.M. (1981). Genesis of
1,2-dimethylhydrazine induced colon cancer. A light and electron-
microscopic study. Arch. Pathol. Lab. Med., 105, 29-37.
GREENSTEIN, A.J., GENNUSO, R., SACHAR, D.B. & 4 others. (1985).
Extraintestinal cancers in inflammatory bowel disease. Cancer,
56, 2914.
ISABELL, G. & LEVIN, B. (1988). Ulcerative colitis and colon cancer.
In Luk, G.D. (ed.), Gastroenterology Clinics of North America,
17, 773. Saunders: Philadelphia.
KRAUSE, JR., AYUYANG, H.Q. & ELLIS, L.D. (1985). Occurrence of
three cases of carcinoma in individuals with Crohn's disease
treated with metronidazole. Am. J. Gastro., 80, 978.
LASHNER, B.A., HEIDENREICH, P.A., SU, G.L., KANE, S.V. &
HANAVER, S.B. (1989). Effect of folate supplementation on the
incidence of dysplasia and cancer in chronic ulcerative colitis.
Gastroenterology, 97, 255.
LAURITSEN, K., HANSEN, J., RYDE, M. & RASK-MADSEN, J. (1984).
Colonic azodisalicylate metabolism determined by in vivo dialysis
in healthy volunteers and patients with ulcerative colitis. Gastro-
enterology, 86, 1496-1500.
LIU, Y., SCHMELTZ, I. & HOFFMAN, D. (1974). Chemical studies on
tobacco smoke. Quantitative analysis of hydrazine in tobacco and
cigarette smoke. Anal. Chem., 46, 885.
MCGARRITY, T.J., PEIFFER, L.P. & COLONY, P.C. (1988). Cellular
proliferation in proximal and distal rat colon during 1,2-
dimethylhydrazine induced carcinogenesis. Gastroenterology, 95,
343-348.
MEYERS, S., SACHAR, D.B., PRESENT, D.H. & JANOWITZ, H.D.
(1987). Olsalazine sodium in the treatment of ulcerative colitis
among patients intolerant of sulfasalazine. A prospective ran-
domized placebo-controlled, double-blind, dose-ranging clinical
trial. Gastroenterology, 93, 1255.
NAUSS, K.M., LOCNISKAR, M., PAVLINA, T. & NEWBERNE, P.M.
(1984). Morphology and distribution of 1,2-dimethylhydrazine
dihydrochloride-induced colon tumours and their relationship to
gut-associated lymphoid tissue in the rat. JNCI, 73, 915-924.
NIELSEN, O.H. & BONDESEN, S. (1983). Kinetics of 5-aminosalicylic
acid after jejunal instillation in man. Br. J. Clin. Pharmacol., 16,
738.
ROSEN, A., URSING, B., ALM, T. & 10 others (1982). A comparative
study of metronidazole and sulphasalazine for active Crohn's
disease: The cooperative Crohn's Disease Study in Sweden. 1.
Design and methodological considerations. Gastroenterology, 83,
541.
SCHRODER, H. & CAMPBELL, D.E.S. (1972). Absorption, metabolism
and excretion of salicylazosulfapyridine in man. Clin. Pharmacol.
Ther., 13, 539.
SELHUB, J., DHAR, G.J. & ROSENBERG, I.H. (1978). Inhibition of
folate enzymes by sulphasalazine. J. Clin. Inv., 61, 221,
SLOAN, D.A.F., LEISZER, D.M., RICHARDS, G.K., MURRAY, D. &
BROWN, R.A. (1983). Increased incidence of experimental colon
cancer associated with long-term metronidazole therapy. Am. J.
Surg., 145, 66.
SPECK, W.T., STEIN, A.B. & ROSENKRANZ, H.S. (1976). Mutagenicity
of metronidazole: presence of several active metabolites in human
urine. J. Nat. Cancer Inst., 56, 283.
SUNTER, J.P., WRIGHT, N.A. & APPLETON, D.R. (1978). Cell popula-
tion kinetics in the epithelium of the colon of the male rat.
Virchows Arch [B], 26, 275-278.
TOTH, B. (1975). Synthetic and naturally occurring hydrazines as
possible cancer causative agents. Cancer Res., 35, 3693.